Beginning in September 2020, Gland Surgery (GS) adopted the Surgery Journal Editors Group (SJEG) joint statement and pledged to "strive for diversity in the peer review process and among the editorial boards and editorial leaders."
Gland Surgery (Gland Surg; GS, Print ISSN 2227-684X; Online ISSN 2227-8575), launched in May 2012, is an open access, peer-reviewed journal published monthly (quarterly published from 2012 to 2014 and bimonthly published from 2015~2020). GS has been indexed by PubMed/PubMed Central (PMC) and Science Citation Indexed Expanded (SCIE). Its latest impact factor (2021 citation year) is 2.16.
As a monthly published journal, it aims at providing cutting-edge findings and practical information on diagnosis, prevention, and treatment of gland diseases, such as breast, thyroid, adrenal, pancreas surgery and other related fields. Dedicated to the understanding and treatment of gland diseases, this multidisciplinary periodical publishes articles that describe basic, translational and clinical research of gland disease from a range of fields as biomarkers, imaging, pathology, biology and interventional radiology etc. Readers can expect to gain new insights into diagnosis, therapeutic approaches and prognosis of gland diseases.
Currently, more than 100 surgery journals have signed on to this living pledge, which can be found on the American College of Surgeons website under the Surgery Journal Editors Group tab (https://www.facs.org/member-services/sjeg).
We support uniform, defined reporting of the sex used for human, animal, tissue, and cell research in all manuscripts published in GS. If only one sex is studied, authors must include a justification statement explaining why a single-sex study was conducted. All human, animal, tissue, and cell research must also include sex-based data reporting and analysis.